Prostate Cancer

A long-term study found that adding 24 months of antiandrogen therapy with bicalutamide to salvage radiation therapy increased overall survival and prostate cancer–specific survival compared with placebo in men who underwent radical prostatectomy.

The use of multi-parametric magnetic resonance imaging could allow more than a quarter of men with high prostate-specific antigen levels to avoid undergoing transrectal ultrasound-guided prostate biopsy.

A new study is suggesting that by targeting a specific microRNA molecule (miR-141) it may be possible to stop the cascade of events that lead to metastasis in men with prostate cancer.

In prostate cancer patients, a PSA nadir value of > 0.5 ng/mL after radiation therapy and androgen deprivation therapy can identify patients at a high risk of death.

Active surveillance is an excellent alternative to surgery or radiation in patients with low-risk cancers. However, the current methods of ascertaining whether a patient harbors a low-risk cancer are flawed.

A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.

A new study is suggesting it may be possible to shut down the circuits that drive the high tumorigenicity of prostate cancer cells leading to castration-resistant prostate cancer.

Among cancer patients with bone metastases, administration of zoledronic acid every 12 weeks did not increase the risk of skeletal events over 2 years compared with the standard dosing of every 4 weeks.

An increasing percentage of men over the age of 75 who are diagnosed with prostate cancer have distant metastases at the time of diagnosis, according to a new study.

Vascular-targeted photodynamic therapy with padeliporfin was significantly better than active surveillance over a 2-year period in men with low-risk localized prostate cancer.

Six therapies have demonstrated improved survival in metastatic castration-resistant prostate cancer, yet there is insufficient data regarding combination and sequencing of these agents, and predicting response or resistance to them. Prostate cancer patients, researchers, and clinicians alike await the results of key phase III studies in 2017 that could further impact how prostate cancer is managed.

Long-term follow-up showed no reduction in prostate cancer mortality with yearly prostate-specific antigen testing.

The use of radiotherapy was associated with an overall survival benefit in patients with prostate cancer and lymph node involvement who underwent radical prostatectomy and were also treated with androgen-deprivation therapy.

This slide show highlights some of the top prostate cancer news of 2016, including studies on aspirin use and cancer risk, the increased incidence of colorectal tumors in prostate cancer patients, hormone therapy and a link to depression, and more.

Medical researchers at Indiana University Bloomington are reporting that prostate cancer may be much more closely related to Ewing’s sarcoma than previously recognized.

The combination of cabazitaxel and abiraterone was well tolerated and showed antitumor activity in previously treated patients with metastatic castration-resistant prostate cancer.

A new study showed that a 24-gene signature can predict outcomes following postoperative radiotherapy in patients with prostate adenocarcinoma who underwent radical prostatectomy.

Androgen deprivation therapy (ADT), a mainstay of treatment for men with prostate cancer, may raise the risk of dementia, according to a new study.

Pembrolizumab showed clinical activity against some cases of enzalutamide-refractory metastatic castration-resistant prostate cancer.

Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases (liver and lung) fare better with the androgen receptor inhibitor enzalutamide than placebo, according to a new analysis from the phase III AFFIRM trial.

Men who have vasectomies do not have a higher risk of prostate cancer and are not more likely to die from the disease, according to a large, prospective study.

While survival at 10 years was nearly identical (close to 99%), a new study found that localized prostate cancer is more likely to metastasize in men receiving active surveillance compared with those who have surgery or radiation therapy.

A 66-year-old Caucasian man with a history of hypertension, hyperlipidemia, and rheumatoid arthritis was diagnosed with prostate cancer.

In this interview we review recent breast cancer screening guidelines from the ACS and USPSTF, and discuss the changing way that early-stage breast and prostate cancers are being treated.

Investigators think they may have found a strong predictor of which men with prostate cancer will develop resistance to androgen deprivation therapy.

PSA failure in men with localized, intermediate- or high-risk prostate cancer was associated with increased all-cause mortality in only those patients with no or minimal comorbidity.

A model based on a series of PSA tests can predict the time to relapse in prostate cancer patients who underwent radical prostatectomy, according to a new study.

The incidence of early-stage prostate cancer in men 50 years and older continued a decline reported earlier, with lower rates in 2013 compared to 2012. This is a likely result of the October 2011 recommendation from the USPSTF against routine PSA testing in all men.

Noncoding RNA appears to be involved in the epigenetic regulation of prostate cancer, according to findings published in Nature Genetics.

In this interview we discuss PSA screening for prostate cancer, the compromised results of the PLCO trial, and more.